Ann: Prana's PBT2 Reduces Tau Related Cogniti, page-30

re: Ann: Prana's PBT2 Reduces Tau Related... Stayer, I think this is great news. We all suspect any real success against AD is going to have to address a vast range of conditions and interactive chemical processes. This will probably be far too complex for any one drug. Far better to restor the health and defences of the cell and and let nature run the repair process.
[Commenting on the significance of the new data, Rudy Tanzi, the Rose and Joseph Kennedy Professor of Neuroscience at Harvard Medical School and Prana’s Chief Scientific Advisor said, "These findings provide further evidence for PBT2 as a highly attractive therapeutic for Alzheimer's disease that targets both beta amyloid deposition and tangle formation. Translating these dual effects into the clinic could potentially provide tremendous benefit for patients."]
[Associate Professor Adlard will present new data showing that treatment with PBT2 significantly improves cognition and reduces the abundance of tau aggregates through metal mediated mechanisms in a transgenic mouse model of tau overexpression.]
Professor Adlard has also been working with normal age related memory loss. Any solid findings here, along with results from plaque positive prodromal patients in the IMAGINE trial could drive the price up.